康柏西普玻璃体腔注射对糖尿病视网膜病变患者视力的影响  

Effects of Compaq Sipp Intravitreal Injection on Visual Acuity of Diabetic Retinopathy

作　　者：韩姬[1] 王玲[1] 刘伟仙[1] 孙宏亮[1] 蔡维[2] 

机构地区：[1]海南医学院附属医院眼科,海南省海口市570102 [2]湖北医药学院

出　　处：《中国全科医学》2015年第5期502-506,共5页Chinese General Practice

基　　金：湖北省教育厅课题(B20122417)--Avastin对缺氧视网膜Muller细胞水通道蛋白4表达的影响

摘　　要：目的探讨康柏西普玻璃体腔注射治疗糖尿病视网膜病变对于视力的影响。方法选取2014年2—6月在海南医学院附属医院进行诊治的糖尿病视网膜病变患者72例(72眼),根据随机数字表法将其分为治疗组和对照组,各36例。患者均给予玻璃体腔一次性注射药物治疗,对照组注射曲安奈德0.1 ml,治疗组注射康柏西普0.1 ml。在治疗前及治疗后1、3个月采用标准视力表对患者进行最佳矫正视力(BCVA)检查;在治疗前及治疗后1个月进行光相干断层扫描(OCT)检测视网膜厚度;在治疗前及治疗后1个月进行多焦视网膜电流图(mf ERG)检查分析N1波(第1个负波)潜伏期的变化期间;记录治疗后1个月内出现的并发症,包括前房炎性反应、角膜水肿、高眼压等;在治疗后3个月采用中文版低视力者生活质量量表(CLVOOL)对患者进行生活质量的调查。结果两组不同时间BCVA比较,差异有统计学意义(P<0.05);组间比较显示:治疗组治疗后3个月BCVA高于对照组(P<0.05);组内比较显示:两组在治疗后1、3个月BCVA均高于治疗前(P<0.05)。治疗前,两组视网膜厚度、N1波潜伏期比较,差异无统计学意义(P>0.05);治疗组治疗后1个月视网膜厚度低于对照组,N1波潜伏期短于对照组(P<0.05);治疗组与对照组在治疗后1个月视网膜厚度低于治疗前,N1波潜伏期短于治疗前(P<0.05)。在治疗后1个月,治疗组前房炎性反应、角膜水肿、高眼压并发症发生率均低于对照组(P<0.05)。治疗后3个月,治疗组自理能力、活动能力、社交与心理评分均高于对照组(P<0.05)。结论康柏西普玻璃体腔注射治疗糖尿病视网膜病变能有效改善视网膜功能,安全性更好,从而有利于视力的快速恢复,提高生活质量。Objective To investigate the effects of Compaq Sipp intravitreal injection on the visual acuity of diabetic retinopathy. Methods 72 patients（ 72 eyes） with diabetic retinopathy treated in the Affiliated Hospital of Hainan Medical University from February to June,2014 were selected and equally divided into treatment group 36 cases and control group 36 cases be means of random number table. All patients were given a single injection in vitreous cavity： the control group were given Triamcinolone Acetonide in 0. 1 ml,and the treatment group were given Compaq Sipp in 0. 1 ml. This study checked all patients＇ the best- corrected visual acuity by standard visual acuity chart before treatment,1 month and 3 months after treatment,examined the retinal thickness by optic coherence tomography（ OCT） before treatment and 1 month after treatment,measured and analyzed the variance range of the implicit time of N1 wave（ the first negative wave） by multifocal electroretinogram（ mf ERG） before treatment and 1 month after treatment,recorded the incidence of complications appeared within the firth month after treatment including anterior chamber inflammation,cornea edema and ocular hypertension and investigated the patients about their life quality by CLVOOL 3 months after treatment. Results The BCVA at different time was significantly different between the two group（ P〈0. 05）; inter- group comparison showed that the BCVA in treatment group was higher than that in control 3 months after treatment（ P〈0. 05） and intra- group comparison showed that 1 month and 3 months after treatment,the BCVA of both groups were all higher than before（ P〈0. 05）. The retinal thickness and N1 latency before treatment between the two groups were not statistically significant（ P〈0. 05）; 1 month after treatment,the retinal thickness of the treatment group was lower and N1 latencies were shorter than those of control group（ P〈0. 05） and in both groups the retinal thickness was lower and N1 latencies was short

关 键 词：康柏西普 玻璃体内注射 糖尿病视网膜病变 视力 曲安奈德 

分 类 号：R587.26[医药卫生—内分泌]